Clinical Trial

Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework
Trial Details
NCT Number NCT07673081
Lead Sponsor Pfizer
Collaborators: Ividence
Conditions Respiratory Syncytial Virus (RSV)
Enrollment 293,334 participants
Start Date 2026-06-20
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-29